{"groups":[{"description":"Patients receive ipatasertib 400 mg PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients undergo biopsies and blood sample collection on study.","id":"FG000","title":"Treatment (Ipatasertib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never Start Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Mutation Status Not Confirmed"},{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Complicating Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"29"}],"comment":"Primary efficacy analysis set","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients with tumors harboring E17K mutations in AKT1, 2, and 3, as well as Q79K and L52R mutations in AKT1, were eligible for sub-protocol Z1K. The mutation status was determined by an NCI-MATCH approved laboratory for all patients in this arm, they had to be confirmed by the NCI-MATCH central assay to be included in primary analysis.","recruitmentDetails":"Subprotocol Z1K was activated on July 25, 2019. Thirty-five patients were enrolled on EAY131-Z1K between August 8, 2019, and November 11, 2020. All patients were enrolled on the basis of the outside lab assay results."}